Skip to main content
IMRX
NASDAQ Life Sciences

Immuneering Extends Cash Runway to Q4 2028 as Phase 3 Pancreatic Trial Enrollment Runs Ahead of Schedule

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$4.02
Mkt Cap
$260.084M
52W Low
$3.38
52W High
$8.48
52W Position info
19% above low
Off High info
53% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

IMRX sits 19% above its 52-week low of $3.38.

Summary

Immuneering ended Q3 with $166.1 million in cash and now expects that to fund operations into Q4 2028, while expanding its Phase 3 pancreatic cancer trial to about 570 patients and pushing its next Phase 2 data update to 1H 2027.


Key Events · Earnings and Guidance · IMRX

  • Cash Runway Extended to Q4 2028

    Cash, cash equivalents and marketable securities were $166.1 million at September 30, 2026, versus $217.0 million at December 31, 2025; the company now expects funding into Q4 2028.

  • Phase 3 Enrollment Target Raised to 570

    Enrollment in the pivotal MAPKeeper 301 trial is ahead of schedule, so the target expands from 510 to approximately 570 patients, with potential to accelerate the current mid-2028 topline guidance.

  • Phase 2 Pancreatic Data Slips to 1H 2027

    Follow-up in the 55-patient atebimetinib + mGnP arm is being extended because patients are living longer than projected; the topline update is now expected in the first half of 2027.

  • R&D Spend and Loss Widen

    Q3 2026 R&D expense was $20.7 million versus $10.9 million a year earlier, and net loss was $24.2 million, or $0.37 per share, compared with $15.0 million, or $0.38 per share.


Analysis · IMRX · Life Sciences

This is more than a cash print: Immuneering now says its $166.1 million in cash and securities funds operations into Q4 2028, and it is expanding the pivotal MAPKeeper 301 trial from 510 to 570 patients while holding out the possibility of pulling the mid-2028 topline readout forward. On the Phase 2 side, follow-up in the 55-patient first-line pancreatic cancer cohort is being extended because patients are living longer than modeled, pushing the next data update to 1H 2027. The trade-off is a heavier burn: quarterly R&D jumped to $20.7 million from $10.9 million a year ago and the net loss widened to $24.2 million. For a clinical-stage company, a longer runway plus faster enrollment removes the most immediate financing overhang, though the delayed Phase 2 readout means the next hard efficacy datapoint is roughly two quarters further out.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IMRX was trading at $4.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $260.1M. The 52-week trading range was $3.38 to $8.48. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IMRX - Latest Insights

IMRX
Oct 29, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.02
Real-time Price: $3.60 info
Change: -$0.420 (-10%) info
Market Cap: $233.795M info
IMRX
Sep 28, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.36
Real-time Price: $3.60 info
Change: -$0.760 (-17%) info
Market Cap: $233.795M info
IMRX
Aug 05, 2026, 7:41 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.23
Real-time Price: $3.60 info
Change: -$0.630 (-15%) info
Market Cap: $233.795M info
IMRX
Jul 21, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.51
Real-time Price: $3.60 info
Change: -$0.910 (-20%) info
Market Cap: $233.795M info
IMRX
Jun 15, 2026, 4:12 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.19
Real-time Price: $3.60 info
Change: -$0.590 (-14%) info
Market Cap: $233.795M info